Sethuraman V - Search Results

1

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.

Wang Y, Zhou L, Dutreix C, Leroy E, Yin Q, Sethuraman V, Riviere GJ, Yin OQ, Schran H, Shen ZX. Wang Y, et al. Among authors: sethuraman v. Br J Clin Pharmacol. 2008 Jun;65(6):885-92. doi: 10.1111/j.1365-2125.2008.03150.x. Epub 2008 Apr 1. Br J Clin Pharmacol. 2008. PMID: 18384443 Free PMC article.

2

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.

Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H. Tanaka C, et al. Among authors: sethuraman v. Clin Pharmacol Ther. 2010 Feb;87(2):197-203. doi: 10.1038/clpt.2009.208. Epub 2009 Nov 18. Clin Pharmacol Ther. 2010. PMID: 19924121 Clinical Trial.

3

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H. Yin OQ, et al. Among authors: sethuraman v. Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015. Clin Ther. 2009. PMID: 20110053 Clinical Trial.

4

Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.

Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H. Tanaka C, et al. Among authors: sethuraman v. J Clin Pharmacol. 2011 Jan;51(1):75-83. doi: 10.1177/0091270010367428. Epub 2010 Aug 11. J Clin Pharmacol. 2011. PMID: 20702754 Clinical Trial.

5

A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials.

Young TC, Srinivasan S, Vetter ML, Sethuraman V, Bhagwagar Z, Zwirtes R, Narasimhan P, Chuang T, Smyth BJ. Young TC, et al. Among authors: sethuraman v. J Clin Pharmacol. 2017 Sep;57(9):1079-1087. doi: 10.1002/jcph.913. Epub 2017 May 16. J Clin Pharmacol. 2017. PMID: 28510323 Free PMC article. Review.

6

Sample size calculation for the Power Model for dose proportionality studies.

Sethuraman VS, Leonov S, Squassante L, Mitchell TR, Hale MD. Sethuraman VS, et al. Pharm Stat. 2007 Jan-Mar;6(1):35-41. doi: 10.1002/pst.241. Pharm Stat. 2007. PMID: 17323313

7

Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.

Sethuraman V, Sun Q. Sethuraman V, et al. Pharm Stat. 2009 Apr-Jun;8(2):113-24. doi: 10.1002/pst.338. Pharm Stat. 2009. PMID: 18481273

8

On power and sample size calculation in ethnic sensitivity studies.

Zhang W, Sethuraman V. Zhang W, et al. Among authors: sethuraman v. J Biopharm Stat. 2011 Jan;21(1):18-23. doi: 10.1080/10543406.2010.494266. J Biopharm Stat. 2011. PMID: 21191851

9

Balanced 2(n) factorial designs when observations are spatially correlated.

Sethuraman V, Raghavarao D. Sethuraman V, et al. J Biopharm Stat. 2009;19(2):332-44. doi: 10.1080/10543400802622543. J Biopharm Stat. 2009. PMID: 19212884

10

Statistical consideration in testing for assay sensitivity in a "thorough" QT study.

Sethuraman V, Wu S, Wang J. Sethuraman V, et al. J Biopharm Stat. 2010 May;20(3):641-53. doi: 10.1080/10543400903582042. J Biopharm Stat. 2010. PMID: 20358442

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters